ONCT - Oncternal Therapeutics outlines late-stage study for mantle cell lymphoma candidate

Oncternal Therapeutics (NASDAQ:ONCT) said it will begin a phase 3 trial of ZILO-301, a combination of its experimental monocolonal antibody zilovertamab with Imbruvica (ibrutinib), for mantle cell lymphoma (MCL) in Q3. The study, which will enroll ~250 people, will evaluate the potential benefit for patients who achieve either a partial response or stable disease during a lead-in with ibrutinib only. Patients will receive just ibrutinib daily for four months. Patients with an inadequate response will be randomized (1:1) to receive zilovertamab or placebo in addition to ibrutinib. The primary endpoint is progression-free survival. The most recent interim data from a phase 1/2 trial showed an objective response rate of 85% and a complete response rate of 41% in 27 evaluable patients. See why Seeking Alpha contributor Amit Ghate is bullish on Oncternal.

For further details see:

Oncternal Therapeutics outlines late-stage study for mantle cell lymphoma candidate